药物开发 药物开发
Kristin R Wildsmith1, Arnaud Charil1, Tammie L S Benzinger2
1Eisai Inc., Nutley, NJ, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
概括
在24周内,Lecanemab治疗显著降低了在患有症状的主导性遗传性阿尔茨海默病的参与者中的粉样蛋白PET扫描. 这些发现与阿尔茨海默病模型预测一致.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 生物医学成像技术 生物医学成像技术
背景情况:
- 主导性遗传性阿尔茨海默症网络试验单位 (DIAN-TU) 启动了tau NexGen适应性平台试验,以评估新的阿尔茨海默症治疗方法.
- 该试验始于一种结合疗法,涉及抗tau单克隆抗体etalanetug (E2814) 和抗粉样β抗体lecanemab.
研究的目的:
- 评估lecanemab在降低患有主导性遗传阿尔茨海默病 (DIAD) 的症状个体中的粉样蛋白PET负担的初步疗效.
- 在DIAD群体中提供lecanemab对粉样蛋白PET成像的影响的初步结果.
主要方法:
- 一个II/III期随机,双盲,安慰剂对照试验 (DIAN-TU-001 Tau NexGen) 招募了患有DIAD的参与者.
- 症状群1 (CDR=0.5-1) 接受了开放标签lecanemab6个月,随后随机分配到E2814或安慰剂.
- 粉样蛋白PET ([11C]PiB-PET) 在基线和第24周进行,以评估粉样蛋白负担的变化.
主要成果:
- 从62名有症状的DIAD参与者的24周初步数据显示,平均粉样蛋白PETSUVr从2.06降低到-0.18.
- 在6个月期间,部分体积调整 (PVC) 的SUVr从3.63下降到-0.43.
- 粉样蛋白清除率在老年患者和那些基线粉样蛋白水平较低的患者中更快,与PK/PD建模一致.
结论:
- 在24周后,莱卡涅马布在症状的DIAD参与者中显著减少了粉样蛋白PET负担.
- 观察到的粉样蛋白减少与来自零星阿尔茨海默病研究的药理动力学/药理动力学 (PK/PD) 建模预测一致.
更多相关视频
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
3.3K
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
451
相关概念视频
Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview
1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation
279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
